Treatment of resistance to filgotinib

Filgotinib (Filgotinib) has shown good efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, but drug resistance may occur in some patients. Management of resistance requires comprehensive consideration of the patient's specific circumstances, mechanisms of resistance, and potential alternative treatment options.

The occurrence of drug resistance may be related to individual differences, including genetic factors, disease characteristics, and previous treatment history. When evaluating drug resistance, doctors usually carefully examine the patient's condition changes during the use of filgotinib to observe whether there is significant symptom improvement or indicator change. If a patient fails to achieve the expected therapeutic effect within a certain period of time after receiving the recommended dose of filgotinib, he or she may be considered drug-resistant.

Patients with confirmed drug resistance first need to undergo a comprehensive evaluation, including laboratory tests and imaging evaluation, to determine the specific cause of drug resistance. Sometimes resistance may result from side effects resulting from patient intolerance to treatment, or due to the progression of comorbidities that render an otherwise effective treatment ineffective. In this case, adjusting the medication regimen or adding adjuvant therapy may be a strategy to solve the problem.

If resistance to filgotinib is caused by changes in biomarkers or adaptive changes in the immune system, clinicians may consider using immunomodulatory drugs with other mechanisms. For example, there may be a shift to other types of JAK inhibitors, biologics, or small molecule drugs. These alternative treatments often target different targets, thereby providing patients with new treatment options.

In the process of dealing with drug resistance, patient quality of life and safety are equally important. Doctors need to fully communicate with patients, explain possible treatment changes and their expected effects, and discuss possible side effects of new treatment options. In addition, patients should be followed regularly to monitor their health and response to new treatments.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC9228886/